Emerging treatments for chronic hepatitis C
Authors:
- 1 March 2015
- journal article
- review article
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 114 (3) , 204-215
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
- Ministry of Health, Labour and Welfare
This publication has 66 references indexed in Scilit:
- HCV direct‐acting antiviral agents: the best interferon‐free combinationsLiver International, 2013
- Extensive inflammation of actinic keratoses during interferon α therapy for chronic hepatitis C in a Taiwanese albino womanJournal of the Formosan Medical Association, 2013
- Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalenceHepatology, 2013
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2011
- Telaprevir for Retreatment of HCV InfectionNew England Journal of Medicine, 2011
- The global burden of hepatitis CLiver International, 2009
- Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis CAnnals of Internal Medicine, 2004
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialThe Lancet, 2001
- Side effects of high-dose interferon therapy for chronic hepatitis CJournal of Hepatology, 1996